Sangamo Therapeutics, Inc. (SGMO) Stock Rating Reaffirmed by Wells Fargo & Company

Wells Fargo & Company reissued their outperform rating on shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) in a research note released on Tuesday morning. The firm currently has a $30.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $20.00.

A number of other research analysts also recently issued reports on SGMO. ValuEngine raised shares of Sangamo Therapeutics from a sell rating to a hold rating in a research report on Friday, August 11th. Piper Jaffray Companies set a $8.00 price objective on shares of Sangamo Therapeutics and gave the stock a hold rating in a research report on Thursday, August 10th. BidaskClub downgraded shares of Sangamo Therapeutics from a hold rating to a sell rating in a research report on Saturday, August 5th. Zacks Investment Research raised shares of Sangamo Therapeutics from a hold rating to a buy rating and set a $12.00 price objective on the stock in a research report on Friday, August 18th. Finally, Wedbush reaffirmed a neutral rating and issued a $4.00 price objective (down previously from $6.00) on shares of Sangamo Therapeutics in a research report on Tuesday, May 16th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. Sangamo Therapeutics has an average rating of Hold and a consensus price target of $14.20.

Shares of Sangamo Therapeutics (NASDAQ:SGMO) opened at 13.45 on Tuesday. The stock’s 50 day moving average is $10.50 and its 200-day moving average is $7.26. The stock’s market cap is $1.12 billion. Sangamo Therapeutics has a 12-month low of $2.65 and a 12-month high of $15.05.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. Sangamo Therapeutics had a negative net margin of 246.39% and a negative return on equity of 38.49%. The firm had revenue of $8.30 million for the quarter, compared to the consensus estimate of $5.82 million. During the same quarter in the previous year, the firm earned ($0.38) EPS. The company’s quarterly revenue was up 124.3% compared to the same quarter last year. Equities analysts expect that Sangamo Therapeutics will post ($0.82) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Sangamo Therapeutics, Inc. (SGMO) Stock Rating Reaffirmed by Wells Fargo & Company” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://sportsperspectives.com/2017/09/09/sangamo-therapeutics-inc-sgmo-stock-rating-reaffirmed-by-wells-fargo-company.html.

In other Sangamo Therapeutics news, VP Curt A. Herberts III sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $15.00, for a total transaction of $225,000.00. Following the sale, the vice president now owns 15,833 shares of the company’s stock, valued at approximately $237,495. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Curt A. Herberts III sold 11,474 shares of the business’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $10.44, for a total transaction of $119,788.56. Following the sale, the vice president now directly owns 23,991 shares in the company, valued at approximately $250,466.04. The disclosure for this sale can be found here. In the last three months, insiders have sold 41,474 shares of company stock worth $494,789. 8.10% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in SGMO. Blair William & Co. IL grew its position in Sangamo Therapeutics by 4.3% during the 2nd quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 500 shares during the last quarter. Aperio Group LLC purchased a new stake in Sangamo Therapeutics during the 2nd quarter worth approximately $108,000. Principal Financial Group Inc. grew its position in Sangamo Therapeutics by 6.8% during the 2nd quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 832 shares during the last quarter. Virtu KCG Holdings LLC purchased a new stake in Sangamo Therapeutics during the 2nd quarter worth approximately $124,000. Finally, Fox Run Management L.L.C. purchased a new stake in Sangamo Therapeutics during the 2nd quarter worth approximately $126,000. 63.43% of the stock is currently owned by institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply